Welcome to our dedicated page for CINC news (Ticker: CINC), a resource for investors and traders seeking the latest updates and insights on CINC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CINC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CINC's position in the market.
CinCor Pharma (NASDAQ: CINC) will present Phase 1 clinical data on its lead product candidate, baxdrostat, at the American Society of Nephrology Kidney Week 2022 from November 3-6 in Orlando. Baxdrostat is a selective, once-daily, oral small molecule inhibiting aldosterone synthase, aimed at treating hypertension and chronic kidney disease. The presentation will highlight safety and pharmacokinetics data, suggesting that dosage adjustments may not be needed for patients with renal impairment, thereby expanding its potential user base.
CinCor Pharma has published Phase 1 clinical data for baxdrostat, an oral aldosterone synthase inhibitor, in the journal Hypertension Research. The randomized study showed baxdrostat is well tolerated, with a favorable half-life for once-daily dosing. It effectively reduces plasma aldosterone levels without affecting cortisol. These proof-of-concept findings suggest significant potential for treating hypertension, particularly in patients with treatment-resistant cases. The findings could lead to further clinical advancement of baxdrostat, addressing an urgent medical need.
CinCor Pharma has announced the presentation of Phase 1 clinical data on its lead product candidate, baxdrostat, at the upcoming 29th International Society of Hypertension conference in Kyoto, Japan, from October 12-16, 2022. The data, presented by James Hui, PhD, will cover the safety, pharmacokinetics, and pharmacodynamics of baxdrostat, a selective oral small molecule inhibitor of aldosterone synthase. This compound targets hypertension, a major global health issue affecting up to 20% of the population.
CinCor Pharma announced it will present Phase 2 data from the BrigHtn trial at the 2022 AHA Scientific Sessions. The trial evaluates baxdrostat, a novel oral drug targeting treatment-resistant hypertension. This randomized, double-blind trial aims to demonstrate how baxdrostat can effectively lower blood pressure in patients not responsive to current treatments. The presentation will occur on November 7, 2022, led by Chief Medical Officer Mason Freeman. CinCor aims to address significant unmet needs within hypertension treatment with baxdrostat.
CinCor Pharma announced participation in major investor conferences including Citi's 17th Annual BioPharma Conference from September 6-8, 2022, in Boston, MA, and Morgan Stanley’s 20th Annual Healthcare Conference on September 12-13, 2022, in New York, NY.
Additionally, management will present at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 3:45 PM ET, with a live webcast available. Investors can arrange meetings during these events.
CinCor, established in 2018, focuses on innovative treatments for cardio-renal diseases, with lead drug baxdrostat in clinical development.
CinCor Pharma (NASDAQ: CINC) announced a presentation of Phase 1 clinical data on its lead candidate, baxdrostat, at the ESC Congress from August 26-29, 2022. This oral inhibitor of aldosterone synthase demonstrated promising safety and pharmacokinetic properties in a randomized study involving healthy volunteers. The data supports baxdrostat's potential as a significant treatment for hypertension, particularly in resistant cases, following recent Phase 2 results indicating reduced blood pressure and good tolerability. The presentation will be made by Dr. Mason Freeman on August 28, 2022.
CinCor Pharma, a clinical-stage biopharmaceutical company focused on cardio-renal diseases, has successfully closed an upsized underwritten public offering. This offering includes 8,625,000 shares of common stock and pre-funded warrants, raising around $258.7 million in gross proceeds for the company. The offering price was set at $30.00 per share for common stock and $29.99999 for pre-funded warrants. Goldman Sachs, Morgan Stanley, Jefferies, and Piper Sandler served as joint book-running managers for this transaction.
CinCor Pharma has announced the pricing of its upsized public offering, now totaling 7,500,000 shares of common stock and pre-funded warrants, up from 6,000,000 shares. Each share is priced at $30.00, generating gross proceeds of approximately $225.0 million. The offering includes 4,900,000 shares and pre-funded warrants for 2,600,000 shares with a negligible exercise price. The transaction is expected to close around August 15, 2022. The offering is managed by Goldman Sachs, Morgan Stanley, Jefferies, and Piper Sandler.
CinCor Pharma has announced an underwritten public offering of 6,000,000 shares of its common stock, with an option for underwriters to purchase an additional 900,000 shares. The offering is subject to market conditions and has not yet become effective as the registration statement on Form S-1 is pending SEC approval. The proposed funds will assist in advancing the development of baxdrostat, a drug targeting hypertension and other cardio-renal diseases. Goldman Sachs, Morgan Stanley, Jefferies, and Piper Sandler are managing the offering.
CinCor Pharma announced pivotal updates on its baxdrostat trials aimed at treating uncontrolled hypertension. The Phase 2 HALO trial has completed patient randomization, enrolling 249 patients, with topline data expected in 2H 2022. An open-label extension study will assess the long-term safety of baxdrostat over 52 weeks. This treatment targets patients not achieving blood pressure control despite multiple antihypertensive agents. The study also aims to identify biomarkers that may predict treatment response, with the full data expected by the end of 2023.
